MedTrace Logo

Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors

NCT00025441 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-12-04

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating children with metastatic rhabdomyosarcoma or other malignant mesenchymal tumors.

Conditions

Interventions

BIOLOGICAL

dactinomycin

BIOLOGICAL

filgrastim

DRUG

carboplatin

DRUG

cyclophosphamide

DRUG

doxorubicin hydrochloride

DRUG

epirubicin hydrochloride

DRUG

etoposide

DRUG

ifosfamide

DRUG

vincristine sulfate

PROCEDURE

peripheral blood stem cell transplantation

RADIATION

radiation therapy

Sponsors & Collaborators

  • Children's Cancer and Leukaemia Group

    collaborator OTHER

  • Societe Francaise Oncologie Pediatrique

    collaborator OTHER

  • Societe Internationale d'Oncologie Pediatrique

    lead OTHER

Principal Investigators

  • Heather P. McDowell, MD · Royal Liverpool Children's Hospital, Alder Hey

  • Annabel B.M. Foot · Bristol Royal Hospital for Children

  • Christophe Bergeron · Centre Leon Berard

Study Design

Purpose
TREATMENT

Eligibility

Min Age
6 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-11-30
Completion
2010-03-31

Countries

  • France
  • Ireland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00025441 on ClinicalTrials.gov